Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358631 · ClinicalTrials.gov registry record · Phase 2
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
A Phase 2 study of Depressive Disorder, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 319
- Enrollment target
- 1
- Study location
NCT00358631: Completed Phase 2 study of Depressive Disorder, sponsored by Sanofi.
NCT00358631 is a Phase 2 study of Depressive Disorder that has completed, run by Sanofi. The registered enrollment target is 319 participants, roughly in line with the 325-participant average among 47 other Depressive Disorder trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00358631, a Phase 2 study of Depressive Disorder, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 319 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
Conditions Studied
Interventions
- DRUG SSR149415
Study Locations (1)
New Jersey
- Sanofi-Aventis - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00358631 record still lists
NCT00358631 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 325-participant average among 47 other Depressive Disorder trials with a reported enrollment target.
The record links to 1 condition, with Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which SSR149415 is the first listed.
NCT00358631 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00358631 about?
NCT00358631 is a clinical study titled "An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder". The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
What is the current status of trial NCT00358631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 319 participants. The study started on 2006-07. Estimated completion is 2007-12.
What conditions does trial NCT00358631 study?
This clinical trial studies the following conditions: Depressive Disorder.
What interventions are being tested in trial NCT00358631?
The interventions under investigation include: SSR149415 (DRUG).
Who is sponsoring clinical trial NCT00358631?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00358631 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00358631's enrollment target sits among peer trials
319 9th of 47 higher than 39 of 47 other Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
RECRUITING · Phase 2
-
Depressed Mood Improvement Through Nicotine Dosing 3
RECRUITING · Phase 2
-
Mindfulness Engaged Neurostimulation for Depression
RECRUITING · Phase 2
-
Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension
ACTIVE NOT RECRUITING · Phase 2
-
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05377996 · 319 participants · Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia